$ONCR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Oncorus, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Oncorus, Inc.. Get notifications about new insider transactions in Oncorus, Inc. for free.
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 17 2021 | ONCR | Oncorus, Inc. | Finer Mitchell H. | Director | Option Exercise | A | 16.55 | 12,500 | 206,875 | 12,500 | |
Jun 17 2021 | ONCR | Oncorus, Inc. | Rubin Eric | Director | Option Exercise | A | 16.55 | 25,000 | 413,750 | 25,000 | |
May 04 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 16.76 | 800 | 13,408 | 35,620 | 36.4 K to 35.6 K (-2.20 %) |
May 04 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 15.94 | 22,755 | 362,715 | 36,420 | 59.2 K to 36.4 K (-38.45 %) |
Apr 28 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 15.22 | 17,990 | 273,808 | 59,175 | 77.2 K to 59.2 K (-23.31 %) |
Apr 28 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 15.00 | 211 | 3,165 | 77,165 | 77.4 K to 77.2 K (-0.27 %) |
Apr 28 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 15.00 | 54 | 810 | 77,376 | 77.4 K to 77.4 K (-0.07 %) |
Apr 09 2021 | ONCR | Oncorus, Inc. | Ashburn Theodore | President and CEO | Option Exercise | M | 5.32 | 4,699 | 24,999 | 336,546 | |
Apr 09 2021 | ONCR | Oncorus, Inc. | Ashburn Theodore | President and CEO | Option Exercise | M | 1.81 | 1,900 | 3,439 | 331,975 | |
Apr 09 2021 | ONCR | Oncorus, Inc. | Ashburn Theodore | President and CEO | Buy | M | 5.32 | 4,699 | 24,999 | 23,145 | 18.4 K to 23.1 K (+25.47 %) |
Apr 09 2021 | ONCR | Oncorus, Inc. | Ashburn Theodore | President and CEO | Buy | M | 1.81 | 1,900 | 3,439 | 18,446 | 16.5 K to 18.4 K (+11.48 %) |
Apr 08 2021 | ONCR | Oncorus, Inc. | Queva Christophe | CSO and SVP, Resear ... | Sell | S | 15.01 | 5,300 | 79,553 | 77,430 | 82.7 K to 77.4 K (-6.41 %) |
Dec 16 2020 | ONCR | Oncorus, Inc. | Canute Scott A | Director | Option Exercise | A | 26.00 | 25,000 | 650,000 | 25,000 | |
Dec 09 2020 | ONCR | Oncorus, Inc. | Harbin Stephen | COO and Chief of St ... | Option Exercise | A | 27.99 | 169,000 | 4,730,310 | 169,000 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Finer Mitchell H. | Director | Option Exercise | A | 1.81 | 42,970 | 77,776 | 42,970 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 700,453 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,525,348 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | P | 15.00 | 151,224 | 2,268,360 | 2,377,025 | 2.2 M to 2.4 M (+6.79 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 700,453 | 0 | 2,225,801 | 1.5 M to 2.2 M (+45.92 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | UBS Oncology Impact Fund L.P. | 10% Owner | Buy | C | 0.00 | 1,525,348 | 0 | 1,525,348 | 0 to 1.5 M |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 2,449,761 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Option Exercise | C | 0.00 | 7,499,999 | 0 | 0 | |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 109,612 | 1,644,180 | 312,282 | 202.7 K to 312.3 K (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | P | 15.00 | 445,194 | 6,677,910 | 1,268,344 | 823.2 K to 1.3 M (+54.08 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 202,670 | 0 to 202.7 K |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 202,670 | 0 | 823,150 | 620.5 K to 823.2 K (+32.66 %) |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
Oct 08 2020 | ONCR | Oncorus, Inc. | Flynn James E | Director | Buy | C | 0.00 | 620,480 | 0 | 620,480 | 0 to 620.5 K |
Oct 05 2020 | ONCR | Oncorus, Inc. | Goldberg John Mayer | SVP, Clinical Devel ... | Option Exercise | A | 15.00 | 56,285 | 844,275 | 56,285 |
Page: 1